Filtered By:
Drug: Minocycline

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 88 results found since Jan 2013.

Effects of Minocycline Plus Tissue Plasminogen Activator Combination Therapy After Focal Embolic Stroke in Type 1 Diabetic Rats Basic Sciences
Conclusions— Combination therapy with minocycline plus tPA may be beneficial in ameliorating inflammation and reducing infarction, brain swelling, and hemorrhage after ischemic stroke with diabetes mellitus/hyperglycemia.
Source: Stroke - February 25, 2013 Category: Neurology Authors: Fan, X., Lo, E. H., Wang, X. Tags: Animal models of human disease, Type 1 diabetes, Acute Cerebral Infarction, Embolic stroke, Thrombolysis Basic Sciences Source Type: research

Reducing haemorrhagic transformation after thrombolysis for stroke: a strategy utilising minocycline.
Authors: Blacker DJ, Prentice D, Alvaro A, Bates TR, Bynevelt M, Kelly A, Kho LK, Kohler E, Hankey GJ, Thompson A, Major T Abstract Haemorrhagic transformation (HT) of recently ischaemic brain is a feared complication of thrombolytic therapy that may be caused or compounded by ischaemia-induced activation of matrix metalloproteinases (MMPs). The tetracycline antibiotic minocycline inhibits matrix MMPs and reduces macroscopic HT in rodents with stroke treated with tissue plasminogen activator (tPA). The West Australian Intravenous Minocycline and TPA Stroke Study (WAIMATSS) aims to determine the safety and efficacy ...
Source: Stroke Research and Treatment - December 2, 2014 Category: Neurology Tags: Stroke Res Treat Source Type: research

Intravenous Minocycline in Acute Stroke: A Randomized, Controlled Pilot Study and Meta-analysis Clinical Sciences
Conclusions— In this pilot study of a small sample of acute stroke patients, intravenous minocycline was safe but not efficacious. The study was not powered to identify reliably or exclude a modest but clinically important treatment effect of minocycline. Larger trials would improve the precision of the estimates of any treatment effect of minocycline. Clinical Trial Registration— URL: http://www.anzctr.org.au. Unique identifier: ACTRN12612000237886.
Source: Stroke - August 26, 2013 Category: Neurology Authors: Kohler, E., Prentice, D. A., Bates, T. R., Hankey, G. J., Claxton, A., van Heerden, J., Blacker, D. Tags: Acute Cerebral Hemorrhage, Acute Cerebral Infarction, Neuroprotectors, Other Stroke Treatment - Medical Clinical Sciences Source Type: research

Immune Responses and Anti-inflammatory Strategies in a Clinically Relevant Model of Thromboembolic Ischemic Stroke with Reperfusion
AbstractThe poor clinical relevance of experimental models of stroke contributes to the translational failure between preclinical and clinical studies testing anti-inflammatory molecules for ischemic stroke. Here, we (i) describe the time course of inflammatory responses triggered by a thromboembolic model of ischemic stroke and (ii) we examine the efficacy of two clinically tested anti-inflammatory drugs: Minocycline or anti-CD49d antibodies (tested in stroke patients as Natalizumab) administered early (1  h) or late (48 h) after stroke onset. Radiological (lesion volume) and neurological (grip test) outcomes were evalu...
Source: Translational Stroke Research - September 13, 2019 Category: Neurology Source Type: research

A 2 × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke model
Conclusion In the future, combining these two safe and low cost interventions in the ambulance has the potential to “freeze” the penumbra and improve outcomes in stroke patients. This pre-clinical 2 × 2 design can be easily translated into a pre-hospital clinical trial.
Source: Experimental and Translational Stroke Medicine - October 9, 2014 Category: Neurology Source Type: research

A 2  × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke model
Conclusion In the future, combining these two safe and low cost interventions in the ambulance has the potential to “freeze” the penumbra and improve outcomes in stroke patients. This pre-clinical 2 × 2 design can be easily translated into a pre-hospital clinical trial.
Source: Experimental and Translational Stroke Medicine - October 8, 2014 Category: Neurology Source Type: research

Sequential Therapy with Minocycline and Candesartan Improves Long-Term Recovery After Experimental Stroke
In this study, we hypothesize that opposing actions of minocycline and candesartan on angiogenesis, when administered simultaneously, will reduce the benefit of candesartan treatment. Therefore, we propose a sequential combination treatment regimen to yield a better outcome and preserve the proangiogenic potential of candesartan. In vitro angiogenesis was assessed using human brain endothelial cells. In vivo, Wistar rats subjected to 90-min middle cerebral artery occlusion (MCAO) were randomized into four groups: saline, candesartan, minocycline, and sequential combination of minocycline and candesartan. Neurobehavioral te...
Source: Translational Stroke Research - May 26, 2015 Category: Neurology Source Type: research

Effect of Inflammation on the Process of Stroke Rehabilitation and Poststroke Depression
Conclusions Stroke comprises ischemic stroke and ICH. The immuno-inflammatory process is involved in neural plasticity following events such as a hemorrhage or ischemic stroke. After ischemia, astrocytes, microglia, and MDMs play important roles during rehabilitation with the modulation of cytokines or chemokines, such as TNF-α and IL-1. Moreover, MiRNAs are also important posttranscriptional regulators in these glial mitochondrial responses to cerebral ischemia. ICH involves processes similar and different to those seen in ischemia, including neuronal injury, astrocytic and microglial/macrophage activation, and n...
Source: Frontiers in Psychiatry - April 10, 2019 Category: Psychiatry Source Type: research

Combining Human Umbilical Cord Blood Cells With Erythropoietin Enhances Angiogenesis/Neurogenesis and Behavioral Recovery After Stroke
In conclusion, our results suggest that hUCBC infusion in combination with EPO administration demonstrates therapeutic efficacy in the treatment of stroke-induced injury by promoting neurogenesis and angiogenesis. Further research that delineates the therapeutic mechanism of systemically administered hUCBC and EPO is required. Ethics Statement All experimental procedures involving animals were performed in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U. S. National Institutes of Health and were approved by CHA University Institutional Animal Care & Use Com...
Source: Frontiers in Neurology - April 9, 2019 Category: Neurology Source Type: research

Sex differences in stroke therapies.
Abstract Stroke is the fifth leading cause of death and acquired disability in aged populations. Women are disproportionally affected by stroke, having a higher incidence and worse outcomes than men. Numerous preclinical studies have discovered novel therapies for the treatment of stroke, but almost all of these have been shown to be unsuccessful in clinical trials. Despite known sex differences in occurrence and severity of stroke, few preclinical or clinical therapeutics take into account possible sex differences in treatment. Reanalysis of data from studies of tissue plasminogen activator (tPA), the only curren...
Source: Cell Research - November 23, 2016 Category: Cytology Authors: Sohrabji F, Park MJ, Mahnke AH Tags: J Neurosci Res Source Type: research

Cell-based and pharmacological neurorestorative therapies for ischemic stroke.
Abstract Ischemic stroke remains one of most common causes of death and disability worldwide. Stroke triggers a cascade of events leading to rapid neuronal damage and death. Neuroprotective agents that showed promise in preclinical experiments have failed to translate to the clinic. Even after decades of research, tPA remains the only FDA approved drug for stroke treatment. However, tPA is effective when administered 3-4.5 h after stroke onset and the vast majority of stroke patients do not receive tPA therapy. Therefore, there is a pressing need for novel therapies for ischemic stroke. Since stroke induces rapid...
Source: Neuropharmacology - August 31, 2017 Category: Drugs & Pharmacology Authors: Venkat P, Shen Y, Chopp M, Chen J Tags: Neuropharmacology Source Type: research

Sex differences in stroke therapies
Stroke is the fifth leading cause of death and acquired disability in aged populations. Women are disproportionally affected by stroke, having a higher incidence and worse outcomes than men. Numerous preclinical studies have discovered novel therapies for the treatment of stroke, but almost all of these have been shown to be unsuccessful in clinical trials. Despite known sex differences in occurrence and severity of stroke, few preclinical or clinical therapeutics take into account possible sex differences in treatment. Reanalysis of data from studies of tissue plasminogen activator (tPA), the only currently FDA‐approved...
Source: Journal of Neuroscience Research - November 6, 2016 Category: Neuroscience Authors: Farida Sohrabji, Min Jung Park, Amanda H. Mahnke Tags: Review Source Type: research

Neuroprotection by insulin-like growth factor-1 in rats with ischemic stroke is associated with microglial changes and a reduction in neuroinflammation
Publication date: Available online 14 December 2019Source: NeuroscienceAuthor(s): Ahmad Serhan, Joeri L. Aerts, EWGM Boddeke, Ron KooijmanAbstractWe and others have shown that insulin-like growth factor-1 (IGF-1) is neuroprotective when administered systemically shortly following stroke. In the current study, we addressed the hypothesis that microglia mediate neuroprotection by IGF-1 following ischemic stroke. Furthermore, we investigated whether IGF-1 modulates pro- and anti-inflammatory mediators in ischemic brain with a special reference to microglia. Ischemic stroke was induced in normal conscious Wistar rats by infusi...
Source: Neuroscience - December 16, 2019 Category: Neuroscience Source Type: research

Minocycline inhibits mTOR signaling activation and alleviates behavioral deficits in the Wistar rats with acute ischemia stroke.
CONCLUSION: Minocycline prevents cognitive deficits via inhibiting mTOR signaling and enhancing autophagy process, and promoting the expression of pre-and postsynaptic proteins (synaptophysin and PSD-95) in the brain of the MCAO stroke rats. The potential neuroprotective role of minocycline in the process of cerebral ischemia may be related to mitigating is-chemia-induced synapse injury via inhibiting activation of mTOR signaling. PMID: 32867663 [PubMed - as supplied by publisher]
Source: CNS and Neurological Disorders Drug Targets - August 30, 2020 Category: Drugs & Pharmacology Authors: Wang S, Wang C, Wang L, Cai Z Tags: CNS Neurol Disord Drug Targets Source Type: research